Muscarinic type-1 receptors contribute to IK,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Jordi Heijman - , University of Duisburg-Essen, Maastricht University (Author)
  • Dorit Kirchner - , University Hospital Carl Gustav Carus Dresden, Institute of Pharmacology and Toxicology (Author)
  • Franziska Kunze - , University Hospital Carl Gustav Carus Dresden, Institute of Pharmacology and Toxicology (Author)
  • Eva Maria Chrétien - , University Hospital Carl Gustav Carus Dresden, Institute of Pharmacology and Toxicology (Author)
  • Martina B Michel-Reher - , Johannes Gutenberg University Mainz (Author)
  • Niels Voigt - , University of Duisburg-Essen (Author)
  • Michael Knaut - , Department of Cardiac Surgery (at Dresden Heart Centre), University Hospital Carl Gustav Carus Dresden (Author)
  • Martin C Michel - , Johannes Gutenberg University Mainz (Author)
  • Ursula Ravens - , Institute of Pharmacology and Toxicology, University Medical Center Freiburg (Author)
  • Dobromir Dobrev - , University of Duisburg-Essen, Institute of Pharmacology and Toxicology (Author)

Abstract

BACKGROUND: Basal and acetylcholine-gated inward-rectifier K+-currents (IK1 and IK,ACh, respectively) are altered in atrial fibrillation (AF). Gi-protein-coupled muscarinic (M) receptors type-2 are considered the predominant receptors activating IK,ACh. Although a role for Gq-coupled non-M2-receptor subtypes has been suggested, the precise regulation of IK,ACh by multiple M-receptor subtypes in the human atrium is unknown. Here, we investigated M1-receptor-mediated IK,ACh regulation and its remodeling in chronic AF (cAF).

METHODS AND RESULTS: M1-receptor mRNA and protein abundance were increased in atrial cardiomyocyte fractions and atrial homogenates from cAF patients, whereas M2-receptor levels were unchanged. The regulation of IK,ACh by M1-receptors was investigated in right-atrial cardiomyocytes using two applications of the M-receptor agonist carbachol (CCh, 2μM), with pharmacological interventions during the second application. CCh application produced a rapid current increase (Peak-IK,ACh), which declined to a quasi-steady-state level (Qss-IK,ACh). In sinus rhythm (Ctl) the selective M1-receptor antagonists pirenzepine (10nM) and muscarinic toxin-7 (MT-7, 10nM) significantly inhibited CCh-activated Peak-IK,ACh, whereas in cAF they significantly reduced both Peak- and Qss-IK,ACh, with no effects on basal inward-rectifier currents in either group. Conversely, the selective M1-receptor agonist McN-A-343 (100μM) induced a current similar to the CCh-activated current in Ctl atrial cardiomyocytes pretreated with pertussis toxin to inhibit M2-receptor-mediated Gi-protein signaling, which was abolished by MT-7. Computational modeling indicated that M1- and M2-receptors redundantly activate IK,ACh to abbreviate APD, albeit with predominant effects of M2-receptors.

CONCLUSION: Our data suggest that Gq-coupled M1-receptors also regulate human atrial IK,ACh and that their relative contribution to IK,ACh activation is increased in cAF patients. We provide novel insights about the role of non-M2-receptors in human atrial cardiomyocytes, which may have important implications for understanding AF pathophysiology.

Details

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalInternational journal of cardiology
Volume255
Publication statusPublished - 15 Mar 2018
Peer-reviewedYes

External IDs

PubMedCentral PMC5815374
Scopus 85041654494

Keywords

Keywords

  • Acetylcholine/pharmacology, Atrial Fibrillation/metabolism, Cells, Cultured, Chronic Disease, Dose-Response Relationship, Drug, Heart Atria/metabolism, Humans, Muscarinic Antagonists/pharmacology, Myocytes, Cardiac/drug effects, Potassium Channels, Inwardly Rectifying/biosynthesis, Receptor, Muscarinic M1/antagonists & inhibitors, Up-Regulation/drug effects